🔴 SYNCHRONIZE-MASLD @NatureMedicine
Survodutida 6,0 mg semanal en obesidad + MASLD de riesgo (fase 3, 48 sem):
📉 ≥30% reducción de grasa hepática (MRI-PDFF): 84,2% vs 24,3% placebo
🫀 −12,2% de peso vs −1,0%
🔬 61% normalizó la grasa hepática (<5%)
Mejoras además en cT1, ALT, AST, rigidez por VCTE y perfil cardiometabólico. Sin DILI, pancreatitis ni cáncer adjudicados.
Doble agonismo GCGR/GLP-1: efecto hepático más allá de la pérdida de peso.
🔗 https://t.co/pmJiAkTArh
#ADA2026 #ADAScisessions
COMPETE SWITCH study
People with type 2 diabetes who were increased to semaglutide
2 mg were as likely to achieve an HbA1c less than 7% and more
likely to achieve greater than 5% weight loss than those who were switched to tirzepatide 2.5/5 mg , in real-world data #ada2026 #adascisessions
https://t.co/DdxdXi6NZy
Retatrutide in adults with obesity over 104 weeks in the highest dose group had 30.3% weight loss.
Nearly 2/3 reached BMI < 30
1 in 3 reached BMI < 25
🚨TRANSCEND-T2D-1 full paper is out in Lancet. Retatrutide in T2D with diet and exercise. 40 weeks. Presenting at ADA 2926.
▪️Treatment regimen estimand: 1.94% reduction in A1C, 15.3% WL (Starting A1C of 7.9-8% average)
▪️Importantly, it doesn’t appear any of the arms had fully plateaued yet, but 4mg may have been getting there.
▪️53-59% females in retatrutide treatment arms, starting BMIs around 35-36
▪️Treatment discontinuations due to adverse events: 5%
▪️Nausea 26%, vomiting 18% (placebo had 4% and 2% respectively)
Identification of the acute pancreas-independent actions of GIP vs. GLP-1 in humans-note the profound actions of GIP on HR and DBP https://t.co/KhM4GEifP3
🔬 5 major obesity medicine updates from #ECO2026 — here’s what you need to know 🧵
1/ SURMOUNT-MAINTAIN — Zepbound works, but only if you stay on it.
Full dose → maintained ALL weight loss
Dropped to 5mg → regained ~12 lbs
Switched to placebo → regained up to 43 lbs
67% of placebo patients needed rescue therapy 😳
2/ ATTAIN-MAINTAIN — Oral Foundayo (orforglipron) after Wegovy/Zepbound preserved most weight loss vs. placebo. Transition drugs are viable. 💊
3/ High-dose Wegovy 7.2mg — Early responders lost an average of 27.7% body weight by week 72. Early response = strong predictor of outcomes. 📈
4/ Wegovy PILL (oral semaglutide 25mg) — Early responders lost 21.6% body weight by week 64 vs. 2.7% placebo. An oral GLP-1 that actually works. 🙌
5/ Body composition data — ~84% of weight lost was fat mass. Visceral fat ↓ >30%. Muscle function was preserved. This is the data we needed. 💪
🎯 The big takeaway: Long-term treatment, dose flexibility, and new oral options are shaping the future of obesity care. Personalized = sustainable = best results.
#ObesityMedicine #GLP1 #Tirzepatide #Semaglutide #ECO2026 #MedTwitter
@RTVCes IMPRESENTABLE!Este paso atrás!!Anda keno hay cosas que implementar y modifican los que funcionan😤!! Influencias desde alguna perspectiva que se no escapa a los Endocrinólogos( especialistas que asisten a las personas con DM mas evolucionaras / mas complejas. UN PASO ATRÁS 😩😤!!
Con enfermedad renal crónica tratada con iSGLT2, añadir finerenona, comparado a no hacerlo; se asoció a ↓74% el riesgo de perder >30% de TFGe, mayor beneficio en aquellos que venían con deterioro más rápido. Seguimiento de 18 meses
Diabetes Obes Metab 2026
10.1111/dom.70821